Skip to main content

March's Most Popular Stories

Published: 3/27/23 3:06 pm
By Arvind Sommi

In case you missed them, below you’ll find our top stories from March 2023. This month’s best stories cover a wide variety of topics including a preview of upcoming diabetes therapies, new dietary and nutrition advice, landmark decreases in insulin costs, and more! 

1. Time to Eat? Why Timing Matters for People With Diabetes

Do people with diabetes need to eat at regular intervals? Is late night snacking ok? What about intermittent fasting? Learn more about why timing matters when eating if you have diabetes.

2. New Vertex Type 1 Stem Cell Therapy Gets FDA Nod to Enter Clinical Trials

The FDA announced that a new type 1 diabetes stem cell therapy from Vertex has been cleared to enter clinical trials in the United States. The therapy, which hopes to avoid the need for immunosuppressive drugs when replacing damaged insulin-producing cells in someone with type 1 diabetes, is scheduled to enter clinical trials in the first half of 2023.

3. Medicare to Expand CGM Coverage for People with Type 2 Diabetes

Medicare will begin covering continuous glucose monitors (CGMs) for a broader group of T2D patients beginning in April.

4. Five Best Diets for Diabetes

The U.S. News & World Report recently released its 2023 list of the best diets for people with diabetes. See which diets made the list, and the benefits and drawbacks of each.

5. Eli Lilly to Cut Price of Insulin by 70%, Cap Insulin Costs at $35 a Month

Eli Lilly announced today that it will cut the list prices for its most commonly prescribed insulins, including Humalog and Humulin, by 70%. The drug maker will also expand a program that caps out-of-pocket insulin costs for patients at $35 per month.

6. Novo Nordisk and Sanofi Announce Plans to Cut Insulin Prices

Following Eli Lilly’s recent announcement of a $35 monthly limit on out-of pocket costs, Sanofi announced a $35 cost cap on Lantus, and Novo Nordisk pledged to reduce the prices of several of its insulin varieties by as much as 75%. Both companies’ cuts will take effect next year.

What do you think?

About the authors

Arvind Sommi joined the diaTribe Foundation in 2021 after graduating from the University of Florida with a degree in Biology. Sommi is an Editor for diaTribe Learn. Arvind Sommi joined... Read the full bio »